NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Furthermore, if the MHRA can’t expand beyond the applied indication, then explain how DCVax-L ended up on the High-Cost Drug list with an expanded indication.

The list has many entries that simply state "cancer" as the indication w/o specifying. And all the others are not tumor agnostic.

The list.

The column is just descriptive. It does not decide what is actually approved. If a drug on this list is approved, then the provider can try to get reimbursement for using it per the terms. The least useful process is the IFR that allows a patient to say why they are somehow different and thus should be entitled to have the drug paid for.